1.92
+0.02(+1.05%)
Currency In USD
| Previous Close | 1.9 |
| Open | 1.91 |
| Day High | 1.94 |
| Day Low | 1.85 |
| 52-Week High | 14.5 |
| 52-Week Low | 1.74 |
| Volume | 131,833 |
| Average Volume | 319,617 |
| Market Cap | 92.35M |
| PE | -1.22 |
| EPS | -1.58 |
| Moving Average 50 Days | 2.36 |
| Moving Average 200 Days | 4.26 |
| Change | 0.02 |
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
GlobeNewswire Inc.
Dec 12, 2024 12:00 PM GMT
RJVA-001 was successfully delivered in large animal Yucatan pig models at low total viral dose Results confirm ability to directly target pancreas with novel delivery catheter and route of administration Local delivery of RJVA-001 achieved therapeut
Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
GlobeNewswire Inc.
Dec 09, 2024 12:00 PM GMT
BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today annou
Fractyl Health to Participate in the Upcoming December Conferences
GlobeNewswire Inc.
Nov 26, 2024 12:00 PM GMT
BURLINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today annou